1347 related articles for article (PubMed ID: 30810243)
21. Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents.
Santoni M; Romagnoli E; Saladino T; Foghini L; Guarino S; Capponi M; Giannini M; Cognigni PD; Ferrara G; Battelli N
Biochim Biophys Acta Rev Cancer; 2018 Jan; 1869(1):78-84. PubMed ID: 29126881
[TBL] [Abstract][Full Text] [Related]
22. Blocking MARCO
Ding L; Qian J; Yu X; Wu Q; Mao J; Liu X; Wang Y; Guo D; Su R; Xie H; Yin S; Zhou L; Zheng S
Cancer Lett; 2024 Feb; 582():216568. PubMed ID: 38065400
[TBL] [Abstract][Full Text] [Related]
23.
He L; Xu K; Niu L; Lin L
Pharm Biol; 2022 Dec; 60(1):1710-1720. PubMed ID: 36086826
[TBL] [Abstract][Full Text] [Related]
24. Increased OIT3 in macrophages promotes PD-L1 expression and hepatocellular carcinogenesis via NF-κB signaling.
Wen J; Yang S; Yan G; Lei J; Liu X; Zhang N; Zhang J; Deng H; Wu L; Li Y
Exp Cell Res; 2023 Jul; 428(2):113651. PubMed ID: 37201744
[TBL] [Abstract][Full Text] [Related]
25. Bromo- and extraterminal domain protein inhibition improves immunotherapy efficacy in hepatocellular carcinoma.
Liu C; Miao X; Wang Y; Wen L; Cheng X; Kong D; Zhao P; Song D; Wang X; Ding X; Xia H; Wang W; Sun Q; Gong W
Cancer Sci; 2020 Oct; 111(10):3503-3515. PubMed ID: 32726482
[TBL] [Abstract][Full Text] [Related]
26. Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression.
Pu Y; Ji Q
Front Immunol; 2022; 13():874589. PubMed ID: 35592338
[TBL] [Abstract][Full Text] [Related]
27. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.
Chew V; Lai L; Pan L; Lim CJ; Li J; Ong R; Chua C; Leong JY; Lim KH; Toh HC; Lee SY; Chan CY; Goh BKP; Chung A; Chow PKH; Albani S
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5900-E5909. PubMed ID: 28674001
[TBL] [Abstract][Full Text] [Related]
28. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H
Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression.
Fu Y; Mackowiak B; Feng D; Lu H; Guan Y; Lehner T; Pan H; Wang XW; He Y; Gao B
Gut; 2023 Oct; 72(10):1942-1958. PubMed ID: 36593103
[TBL] [Abstract][Full Text] [Related]
30. GOLM1 exacerbates CD8
Chen J; Lin Z; Liu L; Zhang R; Geng Y; Fan M; Zhu W; Lu M; Lu L; Jia H; Zhang J; Qin LX
Signal Transduct Target Ther; 2021 Nov; 6(1):397. PubMed ID: 34795203
[TBL] [Abstract][Full Text] [Related]
31. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
[TBL] [Abstract][Full Text] [Related]
32. TREM2
Tan J; Fan W; Liu T; Zhu B; Liu Y; Wang S; Wu J; Liu J; Zou F; Wei J; Liu L; Zhang X; Zhuang J; Wang Y; Lin H; Huang X; Chen S; Kuang M; Li J
J Hepatol; 2023 Jul; 79(1):126-140. PubMed ID: 36889359
[TBL] [Abstract][Full Text] [Related]
33. M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling.
Zong Z; Zou J; Mao R; Ma C; Li N; Wang J; Wang X; Zhou H; Zhang L; Shi Y
Front Immunol; 2019; 10():1643. PubMed ID: 31379842
[TBL] [Abstract][Full Text] [Related]
34. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
[TBL] [Abstract][Full Text] [Related]
35. Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer.
Yagi T; Baba Y; Okadome K; Kiyozumi Y; Hiyoshi Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Baba H
Eur J Cancer; 2019 Apr; 111():38-49. PubMed ID: 30822683
[TBL] [Abstract][Full Text] [Related]
36. Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice.
Li G; Liu D; Kimchi ET; Kaifi JT; Qi X; Manjunath Y; Liu X; Deering T; Avella DM; Fox T; Rockey DC; Schell TD; Kester M; Staveley-O'Carroll KF
Gastroenterology; 2018 Mar; 154(4):1024-1036.e9. PubMed ID: 29408569
[TBL] [Abstract][Full Text] [Related]
37. TREM-1low is a novel characteristic for tumor-associated macrophages in lung cancer.
Zhang G; Liu H; Huang J; Chen S; Pan X; Huang H; Wang L
Oncotarget; 2016 Jun; 7(26):40508-40517. PubMed ID: 27244892
[TBL] [Abstract][Full Text] [Related]
38. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma.
Jiang G; Shi L; Zheng X; Zhang X; Wu K; Liu B; Yan P; Liang X; Yu T; Wang Y; Cai X
Aging (Albany NY); 2020 Jun; 12(12):11466-11484. PubMed ID: 32579541
[TBL] [Abstract][Full Text] [Related]
39. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma.
Langhans B; Nischalke HD; Krämer B; Dold L; Lutz P; Mohr R; Vogt A; Toma M; Eis-Hübinger AM; Nattermann J; Strassburg CP; Gonzalez-Carmona MA; Spengler U
Cancer Immunol Immunother; 2019 Dec; 68(12):2055-2066. PubMed ID: 31724091
[TBL] [Abstract][Full Text] [Related]
40. Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.
Xu HZ; Li TF; Wang C; Ma Y; Liu Y; Zheng MY; Liu ZJ; Chen JB; Li K; Sun SK; Komatsu N; Xu YH; Zhao L; Chen X
J Nanobiotechnology; 2021 Sep; 19(1):268. PubMed ID: 34488792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]